Elizabeth Weesner (2022) “Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration”, Kansas Journal of Medicine, 15(2), pp. 302–304. doi:10.17161/kjm.vol15.17931.